News

PhaseV to Showcase Innovative Clinical Trial Solutions

PhaseV to Showcase Innovative Clinical Trial Solutions

PhaseV to Showcase Innovations at Major Healthcare and Technology Events

Exploring Machine Learning Solutions for Clinical Trial Optimization

PhaseV, recognized for its pioneering contributions to clinical trial optimization through machine learning, has announced its participation in several key industry events in the upcoming months. As clinical trials continue to evolve, machine learning tools are becoming essential for drug developers looking to improve trial efficiency and address new challenges.

Upcoming Presentations by PhaseV Leaders

Executives from the company will tackle important topics at various prestigious conferences, showcasing the effectiveness of their advanced trial optimization platforms.

European Society For Medical Oncology (ESMO) Congress

PhaseV will be presenting at the ESMO Congress taking place from September 13–17 in Barcelona. This event features the latest research in oncology.

  • Presentation: 1342P: Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status
  • Speakers: Walid Shalata, MD, and Dan Goldstaub, PhD
  • Date/Time: Saturday, September 14

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

This important workshop is scheduled for September 25–27 in Rockville, MD, focusing on regulatory challenges in biopharmaceutical statistics.

  • Presentations:
    • 3823: Comparative Analysis of Immunotherapy Alternatives in Non-Small-Cell Lung Cancer - Elad Berkman, CTO of PhaseV
    • 3806: Model Guided Parameter Optimization for Complex Innovative Trial Designs - Tzviel Frostig, PhD
  • Date/Time: Both presentations will take place on September 26 at 5:45pm EDT

Italian Tech Week

Another exciting event is the Italian Tech Week, happening from September 25–27 in Turin, which will highlight innovative technology in pharmaceutical development.

  • Panel Topic: The Pharma of the Future: Robots, AI, and Adaptive Trials
  • Speakers: Raviv Pryluk, Fred Manby, and Fred Parietti
  • Moderator: Ileana Pirozzi
  • Date/Time: September 25, from 3:02–3:27pm CET

Bayesian Biostatistics Conference Bayes 2024

From October 23–25 in Rockville, PhaseV will delve into groundbreaking discussions on Bayesian biostatistics.

  • Presentations:
    • To Bayes or Not to Bayes: Challenges in Designing Bayesian Adaptive Trials - Raviv Pryluk, PhD
    • The Wolf Will Live with the Lamb: Enhancing Detection in Clinical Trials - Oshri Machluf
  • Date/Times: Raviv will present on October 23 from 2:10–2:30pm EDT, and Oshri will present on October 24 from 11:35–11:55am EDT

Innovation in PhaseV's Platforms

Since its founding, PhaseV's unique machine learning platform has revolutionized the clinical trial landscape, enabling researchers to design and adapt trials more effectively. This technology allows users to quickly analyze a wide range of parameters, aiming for optimal outcomes that align with trial goals.

In addition, PhaseV has introduced a new causal-ML pipeline that reveals hidden signals within clinical data, improving the understanding of treatment effects across various patient groups. This advancement provides invaluable insights to help refine future trial designs, ultimately increasing success rates.

About PhaseV

PhaseV utilizes cutting-edge machine learning techniques to enhance the clinical trial process. The company is dedicated to transforming clinical trial methodologies to ensure that new treatments are distributed to patients more quickly and efficiently. To discover more about their pioneering work, visit www.phaseVtrials.com and connect with them on LinkedIn.

Frequently Asked Questions

What is PhaseV?

PhaseV is an innovative company that focuses on leveraging machine learning to optimize clinical trials, assisting drug developers in improving trial outcomes.

What events will PhaseV be presenting at?

PhaseV will participate in the ESMO Congress, ASA Biopharmaceutical Workshop, Italian Tech Week, and the Bayesian Biostatistics Conference.

How does machine learning facilitate clinical trial design?

Machine learning enables researchers to quickly analyze a multitude of parameters, leading to optimal trial designs that fulfill specific objectives.

Who are some key speakers representing PhaseV?

Key speakers include CEO Raviv Pryluk, CTO Elad Berkman, and Data Scientist Oshri Machluf, who will share their insights and findings at these events.

Where can I learn more about PhaseV's technology?

For more information about PhaseV’s innovative technology, visit their official website at www.phaseVtrials.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.